Kairos Pharma(KAPA)
Focus: Kairos Pharma is a public-stage company focused on cell therapy, antibodies, and small molecules for gene therapy and cell therapy indications. The company operates at a pre-revenue stage with minimal clinical development activity.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$100M
Open Jobs
0
About Kairos Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Kairos Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Aggression
AggressionClinical Trials (1)
NCT05711342The Added Value of an Internet-based Intervention for Treatment of Forensic Psychiatric Outpatients
N/AHelp build intelligence for Kairos Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.